Literature DB >> 20043020

Deal watch : BMS acquires rights for IL-6 inhibitor.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20043020     DOI： 10.1038/nrd3094

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Tocilizumab.

Authors:  Clemens Scheinecker; Josef Smolen; Uma Yasothan; Jeffrey Stoll; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

Review 2.  Interleukin 6: from bench to bedside.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Nat Clin Pract Rheumatol       Date:  2006-11
  2 in total
  2 in total

1.  Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

Authors:  Ningyan Zhang; Liming Liu; Calin Dan Dumitru; Nga Rewa Houston Cummings; Michael Cukan; Youwei Jiang; Yuan Li; Fang Li; Teresa Mitchell; Muralidhar R Mallem; Yangsi Ou; Rohan N Patel; Kim Vo; Hui Wang; Irina Burnina; Byung-Kwon Choi; Hans E Huber; Terrance A Stadheim; Dongxing Zha
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 2.  Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.

Authors:  Zhiqiang An
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.